| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent. Cefalexin is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. |
| Indication |
Used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. |
| Pharmacology |
Ceftibuten is a third-generation cephalosporin antibiotic. |
| Toxicity |
Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
A study with radiolabeled ceftibuten administered to 6 healthy adult male volunteers demonstrated that cis-ceftibuten is the predominant component in both plasma and urine. About 10% of ceftibuten is converted to the trans-isomer is approximately 1/8 as antimicrobially potent as the cis-isomer. |
| Absorption |
Rapidly absorbed following oral administration. |
| Protein Binding |
Ceftibuten is 65% bound to plasma proteins. The protein binding is independent of plasma ceftibuten concentration. |
| Elimination |
Ceftibuten is excreted in the urine; 95% of the administered radioactivity was recovered either in urine or feces. |
| Distribution |
* 0.21 L/kg [adult subjects]
* 0.5 L/kg [fasting pediatric patients] |
| External Links |
|